Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 9/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368919 | 1.00 | HCRTR2 (0.39) | HCRTR2HCRTR1MKNK2TRPV4SCN9A | |
| SCHEMBL2368323 | 0.86 | MKNK2 (0.39) | HCRTR2HCRTR1MKNK2TRPV4GRM4 | |
| SCHEMBL2406007 | 0.79 | HSP90AA1 (0.39) | GRM4 | |
| SCHEMBL31700841 | 0.79 | NOS3 (0.34) | TRPV4SCN9A | |
| SCHEMBL16174927 | 0.78 | RXRA (0.41) | HCRTR2HCRTR1MKNK2TRPV4 | |
| SCHEMBL31456651 | 0.77 | TRPV4 (0.53) | TRPV4GRM4 | |
| SCHEMBL20689171 | 0.77 | TRPV4 (0.53) | TRPV4GRM4 | |
| Hydrochloric Acid SCHEMBL21582294 | 0.76 | TRPV4 (0.51) | TRPV4GRM4 | |
| Hydrochloric Acid SCHEMBL30844823 | 0.76 | TRPV4 (0.51) | TRPV4GRM4 | |
| SCHEMBL22842968 | 0.75 | HCRTR2 (0.37) | HCRTR2HCRTR1MKNK2TRPV4EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | HCRTR2 4404/4885HCRTR1 4325/4885MKNK2 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.